Efficacy and Safety of Platelet Inhibitors

Authors

  • Ornella Binazon In Vitro Drug Safety and Biotechnology, Toronto and Faculty of Pharmacy, University Paris Descartes, Paris
  • Audrey Dubois-Gauche In Vitro drug Safety and Biotechnology, Toronto and Faculty of Pharmacy, University Paul Sabatier, Toulouse, France
  • Radu M Nanau In Vitro drug Safety and Biotechnology, and Department of Pharmacology, Faculty Medicine, University of Toronto, Toronto
  • Manuela G Neuman In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, University of Toronto

DOI:

https://doi.org/10.18433/J3MP4Z

Abstract

Ischemic heart disease is the second leading cause of death in the world. The proportion of deaths resulting from this condition has decreased in the last two decades, mainly as a result of improved primary and secondary prevention of cardiovascular events, as well as the development of patient awareness and medical and pharmacological management. The purpose of the present review is to analyze pathophysiological events leading to platelet involvement in cardiovascular thrombosis, as well as the role of pharmacogenetics in modulating the risk of cardiovascular disorders. The present work was performed using a PubMed search with combinations of key words relevant to the subject in both English and French. In addition to the pharmacokinetic and pharmacodynamic characteristics of platelet inhibitors, this work reviews the efficacy and adverse events observed during the clinical trials with these drugs. This review further summarizes possible therapeutic drug monitoring strategies for antiplatelet drugs. The novelty of this work is the description of the lymphocyte toxicity assay as a specific method of diagnosing and predicting possible idiosyncratic adverse events attributable to antiplatelet medication. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Downloads

Download data is not yet available.

Author Biographies

Ornella Binazon, In Vitro Drug Safety and Biotechnology, Toronto and Faculty of Pharmacy, University Paris Descartes, Paris

International student In Vitro Drug Safety, Toronto, Canada, and Pharm. Student Faculty of Pharmacy, University Paris Descartes, Paris, France

Audrey Dubois-Gauche, In Vitro drug Safety and Biotechnology, Toronto and Faculty of Pharmacy, University Paul Sabatier, Toulouse, France

International Student In Vitro drug Safety and Biotechnology, Toronto and MSc. Faculty of Pharmacy, University Paul Sabatier, Toulouse, France

Radu M Nanau, In Vitro drug Safety and Biotechnology, and Department of Pharmacology, Faculty Medicine, University of Toronto, Toronto

Research Assistant, In Vitro drug Safety and Biotechnology, and Department of Pharmacology, Faculty Medicine, University of Toronto, Toronto

Manuela G Neuman, In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, University of Toronto

CEO In Vitro Drug Safety and Biotechnology

Downloads

Published

2013-01-15

How to Cite

Binazon, O., Dubois-Gauche, A., Nanau, R. M., & Neuman, M. G. (2013). Efficacy and Safety of Platelet Inhibitors. Journal of Pharmacy & Pharmaceutical Sciences, 16(1), 1–39. https://doi.org/10.18433/J3MP4Z

Issue

Section

Review Articles